1-(1,1-dimethyl-butyl)-piperidine | 116435-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(1,1-dimethyl-butyl)-piperidine
• 英文别名: 1-(1,1-Dimethyl-butyl)-piperidin；1-(2-Methylpentan-2-yl)piperidine
• CAS: 116435-89-3
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: SCZOMFZUBVZBJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alpha,alpha-二甲基-1-哌啶乙腈 、 丙基溴化镁 在 乙醚 作用下， 生成 1-(1,1-dimethyl-butyl)-piperidine
  参考文献：
  名称：

  Velghe, Bulletin de la Classe des Sciences, Academie Royale de Belgique, 1925, vol. <5> 11, p. 303

  摘要：

  DOI：

文献信息

• Pyridine and Pyrazine derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20110230483A1

  公开（公告）日：2011-09-22

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供吡啶和吡嗪衍生物，可恢复或增强突变型和/或野生型CFTR的功能，用于治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（肠易激综合征、炎症性肠病、阿片类药物诱导）。还包括含有这些衍生物的药物组合物。
• ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20180099957A1

  公开（公告）日：2018-04-12

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了一种化合物的公式I，包括这些化合物的药物组合物以及使用这些化合物预防或治疗FXR介导或TGR5介导的疾病或症状的方法。
• METHOD
  申请人：The University of Liverpool

  公开号：US20180140608A1

  公开（公告）日：2018-05-24

  The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.

  本发明涉及一种治疗病人疼痛的方法，该方法包括向该病人施用公式（I）化合物或其药学上可接受的盐或溶剂的治疗有效量：其中Q如本文所定义。
• Pyridine and Pyrazine Derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20120277232A1

  公开（公告）日：2012-11-01

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，用于恢复或增强突变和/或野生型CFTR的功能，以治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（IBS，IBD，阿片类药物引起）。还包括含有这些衍生物的制药组合物。
• Amyloid targeting agents and methods of using the same
  申请人：The Regents of the University of California

  公开号：US10370345B2

  公开（公告）日：2019-08-06

  Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

  本文提供了可用于检测淀粉样蛋白或类似淀粉样蛋白的新型分子转子荧光团的设计与合成。与未结合的化合物相比，这些荧光团在与淀粉样蛋白或类似淀粉样蛋白结合时会显示出更强的荧光发射。本文还公开了治疗与淀粉样蛋白或类似淀粉样蛋白相关疾病的方法。